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Abstract: Diabetes mellitus is a pandemic metabolic disease characterized by chronically elevated blood glucose 
concentration due to dysfunction in insulin signaling. Diabetics are prone to vascular injury and end-organ damage 
such as nephropathy, retinopathy and neuropathic pain. Methylglyoxal is generated through carbohydrate, lipid and 
protein metabolic pathways which are all found to be increased in diabetes. Moreover, methylglyoxal is highly re-
active with various cellular and interstitial molecules such as proteins and phospholipids forming stable adducts 
and advanced glycation end products. Elevated methylglyoxal is associated with insulin resistance, pancreatic -
cell cytotoxicity, and endothelial dysfunction that accelerates retinopathy. Additionally, elevated methylglyoxal is 
associated with hyperalgesia and neuronal inflammation associated with neuropathic pain. Methylglyoxal might 
represent a potential therapeutic target in diabetes and associated complications. 
Keywords: Diabetes, endothelial dysfunction, glucose, insulin, methylglyoxal, nephropathy, neuropathic pain, retinopathy. 
1. INTRODUCTION 
 Diabetes mellitus (DM) is a pandemic metabolic disease char-
acterized by a chronically elevated blood glucose concentration 
(hyperglycemia) due to insulin signaling dysfunction. This is attrib-
uted to insufficient or blunted insulin secretion and/or reduced tis-
sue sensitivity to insulin [1]. The incidence of diabetes mellitus is 
increasing throughout the world and numbers are expected to reach 
592 million by the year 2035, mainly because of the increase in 
obesity [2]. Approximately 50% of diabetics show diabetes compli-
cations by the time they are diagnosed [3]. Approximately 5 million 
people died from diabetes in 2014 globally which accounts for a 
death every 7 seconds [4]. Despite the differences in etiology, clini-
cal presentation, and disease prevalence, secondary complications, 
such as neuropathic pain, occur in both type 1 and 2 diabetes melli-
tus [5]. Diabetes complications lead to a reduced quality of life and 
pose a huge economic burden to the health system and society [5]. 
In 2011 in the UK, the NHS spent almost £24 billion on diabetes, 
30% of which was spent on managing complications, such as neu-
ropathic pain. By 2035, it is estimated that diabetes will cost the 
NHS approximately £40 billion, accounting for 17% of total health 
resource expenditure [6].  
 Among diabetic patients approximately 10% are diagnosed with 
type-1-DM (T1DM) which is mainly attributed to autoimmune 
activity where expressed plasma islet-cell antibodies destroy pan-
creatic -cells [1, 7]. Children under 12 years comprise the majority 
of T1DM patients who require life-long insulin treatment for sur-
vival. However, there are two types of monogenic diabetes which 
are commonly misdiagnosed as T1DM due to early onset of dis-
ease. These are neonatal diabetes (ND) which is diagnosed in the 
first 6 months of life, whereas the second type; maturity-onset dia-
betes of the young (MODY) affects individuals younger than 25 
years, controlled largely through the use of sulphonylureas such as 
glibenclamide [7].  
 The large majority of diabetics, are of type-2-DM (T2DM), 
which is regarded as a complex disease that embraces genetic  
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factors, lifestyle, age, obesity, pregnancy and male gender as risk 
factors [8, 9]. Unlike T1DM, patients with T2DM usually do not 
require insulin to survive since insulin secretion is only partially 
deficient and/or the individual is insulin resistant. Insulin resistance 
is mainly attributed to chronically elevated levels of insulin reduc-
ing sensitivity and is further increased by abdominal fat and hence 
obesity [1]. Reduced insulin secretion may be due to alterations in 
the insulin signaling cascade and/or reduced pancreatic -cell mass. 
However, the extent of pancreatic -cell mass reduction is contro-
versial as some studies stated that 65% loss of pancreatic -cells is 
sufficient to induce diabetes [10] while other studies concluded that 
as little as 10% reduction of pancreatic -cell mass is sufficient to 
initiate diabetes if associated with altered insulin signaling compo-
nents [11].  
1.1. Methylglyoxal and Diabetes  
 In addition to the previously mentioned diabetes complications, 
diabetics suffer from frequent thirst (polydipsia), urination (polyu-
ria) and hunger (polyphagia) [1]. These common complications 
have recently been found to be associated with plasma/tissue meth-
ylglyoxal (MGO) elevation (Table 1). 
 Chronic hyperglycemia is the main DM complication where 
blood glucose concentration exceeds 7mmol/L (125mg/dl) [12]. 
This results in an increasing proportion of glucose metabolism (ap-
proximately 0.5% of glycolysis), passing down alternate pathways 
to generate reactive oxygen species (ROS) such as MGO [13]. 
MGO is highly reactive and forms stable adducts and advanced 
glycation end products (AGE) with various cellular and interstitial 
molecules such as proteins and phospholipids [12, 13]. Upon form-
ing AGE, MGO is trapped intracellularly and subsequently in-
creases oxidative stress (OS) that disrupts the cellular membrane 
integrity and thereby allows MGO leakage to the serum from where 
it can be measured for disease progression and severity [12, 14, 15]. 
Physiological human plasma MGO concentration is approximately 
150nM and increases ranging from two fold [16] to four fold [46] in 
T2DM patients’ plasma. Moreover, glycolysis-derived MGO inter-
acts with cellular proteins and nucleic acids to accelerate AGE pro-
duction resulting in pancreatic -cell cytotoxicity. This exacerbates 
hyperglycemia and hence DM complications [12]. However, clini-
cal studies have failed to significantly correlate MGO to blood glu-
Please provide 
corresponding author(s) 
photograph
size should be 4" x 4" inches
2    Current Drug Metabolism, 2016, Vol. 17, No. 2 Shamsaldeen et al. 
cose concentration due to 2 main technical reasons, (i) firstly it is 
essential to dissociate MGO from protein without causing any DNA 
damage and/or oxidation to accurately measure total MGO, and (ii) 
the heterogeneity of the samples due to diverse patient backgrounds 
[17].  
1.2. Methylglyoxal Sources 
 Being an AGE precursor, MGO levels have been widely studied 
[17]. The 4 main MGO sources are summarized in the following 
formula:  
MGO total = MGO carbohydrates + MGO lipids + MGO proteins + MGO exogenous  
 As shown in Fig. (1), three main integrated metabolic pathways 
are involved in MGO formation: 
1.2.1. Carbohydrates Metabolism 
 Reducing sugars are able to react with amino groups on proteins 
to yield Schiff’s base which is structurally rearranged into Amadori 
product to be subjected to a series of reactions that generate AGE 
[13]. Accordingly, MGO is generated mainly through phosphorylat-
ing glycolysis such as enzymatic metabolism of triose-phosphates 
which was found to be increased in hyperglycemia, but also the 
pentose phosphate shunt, sorbitol pathways such as xylitol metabo-
lism and fourthly glucoxidation [17, 18].  
 The main source of methylglyoxal in physiological systems is 
the metabolism of triose phosphates, glyceraldehyde 3-phosphate 
and glycerone phosphate through non-enzymatic and/or enzymatic 
reactions [19]. In addition, aminoacetone and hydroxyacetone gen-
erated from threonine and acetone metabolism respectively are 
considered as minor endogenous precursors of MGO [20]. In-vitro 
studies showed first order kinetics of non-enzymatic MGO forma-
tion mainly from glyceraldehyde 3-phosphate (90% with catalytic 
rate (Kcat) = 1.55±0.02 X 10
-4 
S
-1
), whereas less MGO was formed 
from glycerone phosphate, also called dihydroxyacetone phosphate 
(15% with Kcat= 1.94±0.02 X 10
-5 
S
-1
) with 2 hours incubation at 
Krebs solution at 37° [19]. The enolisation of glyceraldehyde 3-
phosphate and glycerin phosphate is an essential step to form 3-
phospho 1, 2-eno-diol, an intermediate which fragments through the 
removal of phosphate to form methylglyoxal [19]. Therefore, the 
enolisation rate for glyceraldehyde 3-phosphate was 1.65±0.03x10
-4 
S
-1
, while it was 1.31±0.05x10
-5 
S
-1
 for glycerone phosphate reveal-
ing that glyceraldehyde 3-phosphate is more susceptible to form 
MGO non-enzymatically than glycerone phosphate [19]. Addition-
ally, when triose phosphate isomerase (10 U/ml) was added to glyc-
erone phosphate (100μM) containing Krebs solution at 37°, the rate 
of MGO formation was accelerated with the maximum concentra-
tion of MGO recorded approximately 3μM in contrast to the forma-
tion of MGO in the absence of triose phosphate isomerase which 
was approximately 2.5μM after 20 minutes [19]. In addition to tri-
ose phosphate isomerase, methylglyoxal synthase (MGS) is also 
involved in MGO generation [21]. MGS is a convergent evolution 
product of triose phosphate isomerase with high specificity towards 
dihydroxyacetone phosphate (DHAP) to produce MGO and ortho-
phosphate [21]. MGS isolated from goat liver showed Km= 
0.76mM for DHAP which was inhibited by 90% with orthophos-
phate (40mM) in imidazole-HCl (100μM) buffer pH 7.2 [22]. Glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) oxidizes DHAP 
into D-glycerate 1, 3-bisphosphate that is converted to pyruvate and 
then D-lactate [23]. GAPDH compromised activity was shown in 
diabetics RBC which showed a 3 fold increase in DHAP compared 
to non-diabetics RBC [24]. Therefore, diabetics’ RBC showed 
DHAP accumulation (29-195nM g
-1 
protein) that was correlated 
with increased MGO generation (900-2100pM g
-1 
protein) revealing 
a negative correlation with GAPDH activity [23].  
 Moreover, triose-phosphate accumulation is associated with 
diabetic nephropathy suggesting the involvement of the carbohy-
drate generated MGO pathway in this diabetes complication [25, 
26] (Fig. 1).  
1.2.2. Lipid Metabolism 
 Lipid peroxidation of polyunsaturated fatty acids yields short 
chain; 3-9 carbon molecules of highly reactive aldehyde such as 2-
Alkenol, 4-hydroxy-2-alkenal as well as ketoaldehydes from which 
glyoxal compounds such as MGO are generated from non-
enzymatic and enzymatic metabolism of acetoacetate or acetone 
intermediates, respectively [13, 17]. Acetoacetate is a major ketone 
body (KB) elevated in type 2 diabetics’ plasma [27]. Acetoacetate 
decarboxylase generates acetone which is found to be elevated 
(97mg/dl) in diabetics’ plasma [28]. Acetone is metabolized 
through the monooxygenase CYP2E1 which is mainly found in the 
liver into acetol and then to MGO through NADPH dependent reac-
tions [20, 29]. Moreover, acetol can be metabolized through 
CYP2E1 forming 1, 2-propanediol that is then metabolized through 
1, 2-propanediol gluconeogenesis to form glucose [30, 31].  
 Moreover, lipolysis shares a common intermediate with carbo-
hydrate metabolism; triose-phosphate through -glycero-phosphate 
dehydrogenase-metabolized glycerol [17]. Previous studies found 
that lipolysis is increased in diabetes and suppression of lipolysis 
improves insulin sensitivity and glucose utilization [32, 33].  
1.2.3. Protein Metabolism 
 Numerous in vitro studies demonstrated the vulnerability of 
tyrosine, serine, threonine and glycine rich proteins towards oxida-
tion as these residues are converted through NAD
+ 
dependent L-
threonine dehydrogenase to acetone and aminoacetone intermedi-
ates which are then converted into MGO [13, 17, 34]. In vitro stud-
ies showed that aminoacetone can be converted to MGO through 
either oxidative deamination (mainly) or oxidative transamination 
[34]. The conversion of threonine into aminoacetone occurs in two 
ways. If oxidation occurs before decarboxylation, then the interme-
diate will be 2-aminoacetate which is spontaneously decarboxylated 
to aminoacetone and hence this reaction requires only one enzyme, 
threonine dehydrogenase which is required to convert threonine 
into aminoacetone [34]. However, if decarboxylation occurs before 
oxidation, the intermediate will be 1-aminopropan-2-ol which re-
quires threonine decarboxylase and 1-aminopropan-2-ol dehydro-
genase to yield aminoacetone [34]. Among these two pathways, the 
2-aminoacetate producing reaction is the major pathway [34].  
 Semi-carbazide sensitive amine oxidase (SSAO), which con-
verts aminoacetone into MGO and hydrogen peroxide, is found 
elevated in diabetic plasma; T1DM (621±209mU/l), T2DM 
(619±202mU/l) compared to non-diabetics plasma (352 ± 102mU/l) 
[17, 35]. Protein catabolism is increased by approximately 50% in 
streptozotocin treated rats, and this increased rate of protein catabo-
lism is attributed to insulin resistance and increased glucocorticoids 
production in STZ treated rats [36].  
1.2.4. Exogenous MGO 
 MGO is ingested in food containing heated and processed fats, 
proteins (Maillard reaction) as well as sugars and tobacco [37], 
whereas previous studies revealed that coffee and whiskies are the 
main MGO-containing beverages [38, 39]. Previous study deter-
mined that N-carboxymethyl lysine (CML) levels provide a useful 
marker for total pro-oxidant amounts of AGE [40]. The average 
daily consumption of AGE in total is 16000kU AGE which is ag-
gravated by high temperature processing such as oven frying that 
increases the AGE content of chicken breast to 900kU/g (kilo unit 
AGE per gram of serving size) compared to boiled chicken breast 
(100kU AGE/g) [40]. Chronic consumption of MGO-containing 
food/beverages causes mild liver inflammation as well as fat depo-
sition on parenchymal cells which alters fasting insulin and thereby 
reduces glucose tolerance according to previous research conducted 
on rat hepatocytes [39]. In the Maillard reaction, reducing sugars 
such as glucose interact with free amino groups found in proteins to 
form for instance N-substituted glycosylamine which in the pres-
ence of water goes through Amadori rearrangement to yield  
Amadori product, 1-amino-1-deoxy-2-ketose [41]. The rearranged 
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Amadori product (RAP) is then degraded through 2,3 enolisation to 
form numerous fission products such as acetol, pyruvaldehyde and 
diacetyl compounds at pH7 [41]. These carbonyl compounds are 
highly reactive with amino acids to form aldehydes and -
aminoketones [41]. Previous studies found that Maillard reaction 
products are significantly increased in diabetics’ skin collagen as 
CML, fructoselysine (FL) and pentosidine which are associated 
with accelerated aging [42]. Additionally, CML is significantly 
elevated in diabetic plasma when compared to healthy plasma, and 
such elevation is exacerbated when purely prepared AGE beverages 
were ingested [22]. This elevation was associated with altered vas-
cular function through suppressing the expression and function of 
eNOS as well as stimulating the release of vascular cells adhesion 
molecules (VCAM-1) [37]. 
1.3. Methylglyoxal Metabolism 
 Two glutathione (GSH) dependent pathways contribute to 
MGO metabolism; glyoxalase system (GLO), glyoxalase 1 and 
glyoxalase 2 (GLO1 & GLO2) and aldose reductase, of which GLO 
is the major pathway that converts MGO to non-toxic D-lactate [17, 
 
Fig. (1). Endogenous sources of methylglyoxal (MGO) from glucose, lipid and protein metabolism. (A) Normal condition shows low MGO production from 
glycolysis, lipolysis or proteolysis with major sources represented in bold arrows. (B) Diabetes is associated with increased MGO production from hypergly-
cemia, accelerated lipolysis and proteolysis represented with thick borders and bold arrows which are accompanied by compromised glyoxalase activity. Di-
hydroxyacetone phosphate (DHAP), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), semi-carbazide sensitive amino oxidase (SSAO). 
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43]. In the GLO system, the series of reactions is regulated through 
substrate availability as the substrate of GLO1, hemithioacetal 
(HTA) inhibits GLO2, and the substrate of GLO2, free GSH inhib-
its GLO1 [44, 45]. The maximum enzyme velocity of GLO1 
Vmax= 70.4±4.7mmol min
-1
 l
-1 
of packed erythrocytes) is approxi-
mately 3 fold higher than GLO2 (Vmax= 24±5mmol min
-1
 l
-1 
of 
packed erythrocytes). Moreover, GLO1 possesses higher affinity 
(Km= 0.46±0.04mmol) toward MGO than GLO2 (Km= 
7.88±0.16mmol). Therefore, the rate limiting step of MGO metabo-
lism is the GLO2 activity [46].  
 The other route of metabolism of MGO is through aldose reduc-
tase. Approximately 11% of glucose is metabolized through the 
sorbitol pathway through the bi-modal aldose reductase that acts as 
an aldehyde reductase rather than as a ketone reductase and thereby 
preferentially produces acetol. Acetol is then converted retrospec-
tively to MGO through CYP2E1 to start a futile cycle that depletes 
the intracellular GSH and elevates acetol in diabetic plasma [17]. 
The reduction of MGO through aldose reductase requires NADPH 
to yield 95% acetol and 5% d-lactate [47]. Acetol is then reduced to 
L-1, 2-propanediol through aldose reductase in the presence of 
NADPH, and L-1, 2-propanediol is then metabolized into lactalde-
hyde and lactate through hepatic alcohol dehydrogenase and lactal-
dehyde dehydrogenase, respectively [47, 48]. Aldose reductase 
Kcat toward MGO= 142min
-1
 with Kcat/Km= 1.8x10
7
 M
-1
min
-1
 
[47].  
1.4. Methylglyoxal and Insulin 
 Insulin secretion is a calcium-dependent cascade which starts 
when pancreatic -cells glucose-transporter-1 (GLUT-1) take up 
glucose due to elevated plasma-glucose. This results in ATP syn-
thesis and potassium ATP channels (KATP) closure. Once KATP are 
closed, Calcium ions (Ca
+2
) enter through voltage gated Ca+2 
channels initiating insulin exocytosis [49]. However, glucose is not 
the only insulin release stimulator as lipids and proteins are also 
insulin secretagogues, in addition to other neurotransmitters and 
hormones such as incretins which stimulate insulin secretion inde-
pendently from Ca+2 as illustrated in Fig. (2) [7]. Insulin resistance 
is a complex condition where a normal insulin concentration is not 
sufficient to mediate glucose uptake and utilization. Hence, more 
insulin is released to try to maintain glucose homeostasis [50, 51]. 
MGO has been shown to bind to insulin through targeting arginine 
residues located in chain B and at N-terminus [50]. MGO-modified 
insulin chain B is heavier than free insulin by an additional 126Da 
and is less effective in stimulating glucose uptake and utilization. 
Reduced glucose uptake has been demonstrated in skeletal muscle 
L8 cells and 3T3-L1 adipocytes as well as a 50% reduction in me-
tabolism in H4-II-E hepatocytes [50]. Downstream elements of the 
insulin signaling pathway are also affected. Insulin receptor sub-
strate-1 (IRS-1) phosphorylation and PI3K activity are both sup-
pressed dose dependently following MGO and reversed with MGO 
scavenger; N-acetylcysteine [51] (Table 1).  
 In addition, MGO (100μM) induces cytotoxicity when applied 
to RINmf5 insulin secreting cells in culture [12]. Such an effect is 
comparable to the apoptosis inducing effect of high glucose 
(16mM) on rat pancreatic -cells [12]. These findings suggest that 
MGO might play a major role in progressive stages of diabetes 
where chronic hyperglycemia yields elevated MGO that reduces 
insulin signaling and pancreatic -cell numbers leading to a further 
reduction in insulin secretion [12] (Fig. 2). Moreover, when MGO 
60mg/kg/day was infused in Sprague-Dawley rats for 28 days, it 
resulted in a significant reduction in plasma insulin and a signifi-
cant increase in fasting plasma glucose [52]. 
 Additionally, plasma, pancreatic, muscle and adipocyte tissues 
were all characterized by significant MGO elevation associated 
with significant decrease in glutathione (GSH) and adipocyte 
plasma membrane glucose transporter-4 (GLUT-4) as well as pan-
creatic GLUT-2 [52]. 
 
Fig. (2). Insulin release from pancreatic -cells through calcium dependent 
and independent pathways. GLUT-1 takes up glucose which is metabolized 
through glucokinase (GCK) to glucose-6-phophate which is metabolized in 
the mitochondria to generate ATP. A rise in [ATP] stimulates the closure of 
potassium ATP channels and depolarization that triggers Ca+2 influx. 
Whereas glucagon like peptide-1 (GLP-1) stimulates insulin secretion via an 
exchange protein activated by cAMP (EPAC) and protein kinase A (PKA)-
dependent mechanisms which are activated through cyclic adenosine mono-
phosphate (cAMP). Plus signs indicate stimulation. (A) Normal insulin 
secretion. (B) Methylglyoxal (MGO) is toxic to pancreatic -cells and forms 
insulin-adducts which endows insulin with higher molecular weight and less 
activity. 
 
 Insulin binds to its corresponding tyrosine-kinase coupled endo-
thelial receptor, insulin receptor (IR) which is phosphorylated and 
provides a docking site for insulin receptor substrate-1 (IRS-1) to 
bind. As it exerts tyrosine-kinase activity, IR phosphorylates IRS-1 
to expose an interactive sulfhydryl (SH2) domain which is respon-
sible for activating phosphatidylinositol 3-kinase /protein kinase B 
(PI-3K/PKB) as well as Ras-mitogen activated protein kinase 
(MAPK) pathways. These pathways phosphorylate approximately 
40 cellular targets including Akt-dependent endothelial nitric oxide 
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synthase (eNOS) that generates nitric oxide (NO) to yield endothe-
lium-dependent vasodilation [51, 53, 54, 55]. Therefore, MGO-
induced insulin dysfunction (reduced secretion and increased resis-
tance) might directly cause vascular dysfunction, a common com-
plication in diabetes [54] (Fig. 3). 
1.5. Methylglyoxal and Vasculature 
 Numerous authors have linked elevated MGO levels with vas-
cular and other end organ damage such as nephropathy and neu-
ropathy [56]. Vascular dysfunction is a common complication in 
DM which may culminate with renal failure, blindness and limb 
amputation [57, 58]. As a highly reactive aldehyde, MGO forms 
stable adducts when reacting with multiple macromolecules through 
preferentially targeted aminoacids such as lysine; N-carboxyethyl 
lysine (CEL), MGO-derived lysine-lysine dimer (MOLD), arginine; 
5-methylimidazolone, tetra-hydropyrimidine and argpyrimidine as 
well as sulfhydryl group-containing cysteine which forms stabilized 
S-lactyl cysteine through keto-enol tautoumerism from which CEL 
and MOLD are both elevated in DM [13].  
 MGO inhibits eNOS through inhibiting the phosphorylation of 
serine 1177, thereby inhibiting NO production and vascular relaxa-
tion [57] (Fig. 3). Moreover, MGO (100μM) induces NO produc-
tion and H2O2 generation in rat thoracic aortic smooth muscle cells 
(ASMC) [56]. Furthermore, induced NO reacts with peroxides 
(O.2) forming the highly reactive oxidant peroxynitrite (ONOO-), 
so that NO is bound and thereby physiologically non-functional. In 
addition, ONOO- itself is considered as an essential atherosclerotic 
factor [56]. Immunohistochemical-based observations in kidneys 
from diabetic patients show increased argpyrimidine formation in 
arteries from diabetic patients suggesting MGO induces arterial 
injury as a further DM complication [59].  
 GLO-1-overexpression or MGO scavengers such as diacetyl 
cysteine restores Vascular function in STZ treated animals and is 
accompanied by MGO and AGE reduction [57, 58] (Table 1). 
MGO is also a redox-based cell signaling regulator [56], which 
oxidizes GSH to GSSH through irreversible binding to arginine and 
thereby alters the cellular redox system pushing cells towards oxi-
dative stress-induced apoptosis [50]. MGO blocks insulin-
stimulated eNOS phosphorylation at serine-1177 and threonine-497 
and also inhibited tyrosine phosphorylation of IRS-1 and Akt [54]. 
These effects of exogenous MGO are mimicked by GLO-1 inhibi-
tion [54]. Moreover, in vivo studies on mice administered i.p MGO 
50-75mg/kg/day for 5 consecutive days each week for 7 weeks 
showed significant insulin resistance accompanied with compro-
mised endothelial function. This was attributed to IRS-1 inhibition 
through serine-616 phosphorylation and eNOS signaling suppres-
sion [54] (Fig. 3). Additionally, endothelial dysfunction is accom-
panied by an increase in oxidative stress markers such as the vascu-
lar monocytes chemoattractant peptide-1 (MCP-1) and RAGE ex-
pression in Wistar and Goto-Kakizaki rats [60]. Tetrahydro-
pyrimidine (THP), an AGE product of MGO was elevated in T1DM 
compared to non-diabetics (115.5U μl-1 vs 109.8U μl-1) and such 
elevation was strongly associated with an endothelial dysfunction 
marker, soluble vascular cell adhesion molecule-1 (sVCAM-1) and 
phospholipase-A2 (sPLA2), a low grade inflammatory marker. This 
data suggests elevated MGO is associated with vascular dysfunc-
tion [61].  
 These diabetic vascular complications are commonly associated 
with retinopathy. MGO-derived CML, CEL and hydroimidazalone-
1 (MG-H1) are increased in diabetic wild type (WT) rat retina but 
not in diabetic GLO-1 overexpressing transgenic rats or in non-
diabetic rats. GLO-1 overexpression prevented the generation of 
new capillaries in acellular tissues in central and peripheral regions 
of retina as well as preventing cellular capillary degeneration [62].  
 In addition to all these vascular complications, the lifespan of 
erythrocytes (RBC) is reduced in diabetes. The MGO concentration  
 
 
Fig. (3). Methylglyoxal (MGO) induces vascular dysfunction by interfering 
with insulin signaling. (A) Normal endothelial vasodilation stimulated 
through insulin binding to its insulin receptor (IR) which is phosphorylated 
to expose an intracellular binding site for insulin receptor substrate-1 (IRS-
1) which is phosphorylated upon binding. Phosphorylated IRS-1 provides a 
sulfhydryl (SH2) residue which is then bound with phosphatidylinositol 3-
kinase (PI3K) that phosphorylates protein kinase B (PKB) PKB phosphory-
lates and activates Akt that activates endothelial nitric oxide synthase to 
generate nitric oxide (NO). NO diffuses into smooth muscle cells (SMCs) 
causing vasodilation (VD). (B) MGO reduces insulin secretion through 
pancreatic -cells toxicity, binds to insulin forming the less active insulin-
MGO adduct and inhibiting eNOS phosphorylation. This results in less NO 
production and compromised endothelial vasodilation. 
 
is doubled in diabetics’ RBC and elevated by fourfold in diabetics’ 
plasma compared to non-diabetics’ [63]. MGO accelerates RBC 
suicidal death, eryptosis, through enhancing phosphatidylserine 
exposure on the cell surface, a signal that triggers cell death. Fur-
ther, MGO was shown to reduce ATP and GSH levels in RBCs 
which would accelerate eryptosis [63, 64]. Moreover, ROS elevation 
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Table 1. Methylglyoxal effects on diabetes induction or diabetic complications  
Model  Diabetes related effect Significant findings 
Sprague-Dawley rats MGO 60mg/kg/day for 28 days induces 
insulin dysfunction and hyperglycaemia and 
therefore is concluded as diabetogenic  
• Fasting plasma glucose elevation 
• Insulin release, GLUT-4, PI3-K and adipose glucose uptake 
reduction [52] 
Human insulin, cell culture 
studies on 3T3-L1 adipocytes, L8 
skeletal muscle cells, H4-II-E 
cells and INS-1E cells. 
MGO 10μM-1mM induces insulin resistance 
and thus is considered as diabetogenic  
• Mass spectrophotometry: additional peaks of MGO-bound 
insulin 
• L8-cells showed significant reduction in glucose uptake 
• MGO binds INS-1E cells and reduces Insulin negative 
feedback [50] 
RINmf5 insulin secreting cells MGO 100μM-10mM induces cells toxicity 
and thus is considered as diabetogenic  
• Fragmented nuclei cells elevation recorded microscopically 
and with multiparameter flow cytometry [12]  
Human plasma and erythrocytes  MGO 30-300μM was shown to accelerate 
eryptosis  
• HPLC analysis showed plasma and RBC MGO elevation 
• MGO reduced GSH and ATP in RBC 
• MGO dose dependent annexin-V-positive elevation [63] 
Mouse aortic endothelial cells MGO 500μM induces endothelial 
dysfunction through interfering endothelial 
insulin signalling  
• Western blotting: Inhibiting IRS-1, Akt and eNOS 
phosphorylation [54] 
Human plasma MGO derivatives were associated with 
endothelial dysfunction  
• ELISA measurements showed sVCAM-1 and sPLA2 
elevation associated with THP in T1DM patients [61]  
STZ Wistar-Kyoto rats saphenous 
artery  
MGO elevation was associated with vascular 
function which is a major complication in 
diabetes  
• Mild impairment in cholinergic and sodium nitroprusside 
(SNP) induced vasodilation [58] 
Wistar and Goto-Kakizaki rats MGO induces endothelial dysfunction even 
when ingested (50-75mg/kg/day for 3 
months)  
• Cholinergic vasodilation significant impairment 
• Aortic IHC showed significant reduction in free NO 
production accompanied with increase in superoxide 
generation  
• Western blotting showed significant suppression of 
phosphorylated and total vasodilator stimulated 
phosphoprotein 
• Vascular inflammation through increased monocyte 
chemoattractant peptide-1  
• (MCP-1) [60] 
Normal human LDL, human BJ 
fibroblast AND HepG2 cells and 
Charles River rats 
MGO-bound LDL accelerates vascular 
complications such as atherosclerosis 
• LDL particles significantly decreased through MGO binding 
• Cell free microplate blocked wells showed significant 
aggregation tendency of MGO-bound LDL 
• IHC: MGO increased LDL retention in rats aorta 
• MGO-bound LDL binds significantly more to LDL receptors 
found on HepG2 and BJ cells [66] 
Sprague Dawley rat aortic rings, 
rat aortic and human umbilical 
veins endothelial cells.  
MGO 100μM induces endothelial 
dysfunction, a common diabetes 
complication  
• Cholinergic endothelium dependent vasodilation significant 
impairment accompanied with significant decrease in 
endothelial NO production with suppressed eNOS 
phosphorylation estimated through western blotting [57] 
Mice (TRPA1+/-) HEK 293t cells 
and DRG cultures 
MGO 10mM induces neuropathic pain, a 
major diabetic complication  
• MGO generates large inward current in HEK 293t cells and 
depolarizes the membrane from -100 to +100mV  
• Calcium imaging reveals MGO binding to cysteine preferably 
to induce calcium entry 
• TRPA1 or TRPV1 KO DRG showed significant lack of 
response to MGO [14]  
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Model  Diabetes related effect Significant findings 
Diabetic patients, WT and STZ 
mice 
mice (Glo-/+), mice (Scn-/-), 
human sciatic nerve, mice DRG, 
MGO treated Wistar rats 
MGO 5μM administered systemically into 
rats induces hyperalgesia and neuronal 
inflammation for 3 hours  
• MGO elevation was associated with diabetic neuropathy in 
T2DM patients  
• MGO depolarizes sensory neurons and modifies Nav1.8 to 
increase the neuronal excitation and facilitate nociception 
• MGO slows Nav1.7 inactivation 
• In mice, MGO reduces nerve conduction and increases 
calcitonin gene-related peptide (CGRP) and cyclooxygenase-2 
(COX-2) expression to promote thermal and mechanical 
hyperalgesia in mice 
• MGO increases blood flow to nociceptive cerebral regions 
[43] 
Transgenic GLO-1 and normal 
Wistar rats  
Restoring MGO metabolism prevents 
retinopathy, a common visual complication 
in diabetes  
• Immunoblotting showed significant increase in CEL, CML, 
MG-H1 in diabetic Wistar rats’ retinas suppressed in GLO1 
transgenic rats [62] 
 
in hemodialysis patients (HD) suggests that cell injury may be a 
consequence of methylglyoxal induced RBC injury [17, 65]. 
1.6. Methylglyoxal and Neuropathic Pain 
 Diabetes is one of the leading causes of chronic neuropathic 
pain [5]. Neuropathic pain occurs in both Type 1 and Type 2 diabet-
ics and given the heterogeneity of mechanisms that drives neuro-
pathic pain in patients, it is challenging to identify an optimum 
treatment strategy [5]. Among the major diabetic complications is 
diabetic neuropathy where nociception is exacerbated due to diabe-
tes [14]. A recent study found plasma MGO was approximately 
doubled in diabetics and reached 1M in diabetic individuals with 
hyperalgesia. |This was associated with increased COX-2 expres-
sion and suppressed GLO-1 activity [43]. In mice, MGO induced 
heat hyperalgesia in a dose dependent manner and this was also 
seen when GLO expression was suppressed [43]. Moreover, STZ 
diabetic mice showed GLO suppression and hyperalgesia [43]. 
MGO acutely depolarizes the resting membrane potential in mouse 
sensory neurons increasing their excitability. These changes in ex-
citability were shown to be Nav1.8 –dependent, as they were absent 
in Nav1.8 –KO mice [43]. Molecular studies showed MGO triggers 
changes in Nav1.8 gating through DIII-DIV linker’s arginine resi-
due modification [43]. MGO also increases the release of calcitonin 
gene related peptide (CGRP) in peripheral nerves in STZ-diabetic 
and control mice [43]. These neuronal events are also accompanied 
by an increase in cerebral blood flow to areas associated with noci-
ception [43]. A further molecular mechanism for exacerbation of 
diabetic neuropathy is activation by MGO of human ankyrin tran-
sient receptor potential TRPA1. An effect which was blocked by 
the TRPA1 antagonist (HC030031) [14]. TRPA1 is expressed in 
sensory neurons and mediates nociception through numerous nox-
ious compounds such as the highly reactive electrophile, MGO. 
Sensory neurons from TRPA1 knockout mouse shows no calcium 
influx when treated with MGO Binding of MGO to the cysteine and 
lysine residues of the channel’s N-terminal intracellular domain are 
necessary for channel activation by MGO [14]. 
 MGO facilitates the release of CGRP from vagus and sciatic 
nerves as well as from the skin that contributes to nerve sensitiza-
tion. MGO might contribute to neuropathic pain in diabetes [14]. 
CONCLUSION 
 Diabetes mellitus is a metabolic disorder that is a major health 
burden in most of the countries around the globe. Although numer-
ous therapeutic options are available to control diabetes, these 
medications are targeted mainly toward controlling the blood glu-
cose level through supplying insulin, enhancing insulin secretion, 
enhancing the tissues’ sensitivity towards insulin, interfering with 
glucose absorption or re-absorption. However, diabetic complica-
tions such as retinopathy, neuropathic pain, vascular and renal 
complications are still the main diabetic complications that, in the 
long term, remain largely resistant to these treatments. Numerous 
studies reviewed in this paper show a correlation between MGO 
and diabetes as well as diabetes complications which suggest that 
understanding the actions of MGO might identify therapeutic tar-
gets for treating consequences of diabetes in the future. 
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